Stockreport

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

INmune Bio Inc. - Common stock  (INMB) 
PDF Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 [Read more]